Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Amgen
Sort By
Newest First
1 / 3
1 / 3
COVID-19
Iceland Provides a Picture of the Early Spread of COVID-19 in a Population with a Cohesive Public Health Response
deCODE
PR-M05-20-NI-004
May 01, 2020
Facility
Amgen Selects Location for R&D Facility in ihe South San Francisco Biotechnology Hub
Amgen
PR-M12-19-NI-014
Dec 10, 2019
Partner
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
REVOLUTION Medicines, Inc.
PR-M11-19-NI-004
Nov 05, 2019
Strategic Collaboration
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
Amgen
PR-M10-19-NI-048
Nov 01, 2019
Drug Pricing
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Amgen
PR-M10-19-NI-037
Oct 25, 2019
Positive Results
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients
Amgen
PR-M09-19-NI-056
Sep 27, 2019
Investment
Rumors Suggest Amgen is Interested in Alexion
Nice Insight
PAO-M00-19-NI-001
Sep 04, 2019
M&A
Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits
Amgen
PR-M08-19-NI-083
Aug 29, 2019
KRAS Inhibitor
Amgen Reports Further Success with New KRAS Inhibitor
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-025
Aug 22, 2019
Collaboration
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
Amgen
PR-M05-19-NI-014
May 06, 2019
Launch
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
Amgen Foundation
PR-M04-19-NI-068
Apr 22, 2019
Drug Development
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen
PR-M04-19-NI-054
Apr 17, 2019
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
Nice Insight
PAO-M04-19-NI-015
Apr 10, 2019
Collaboration
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Amgen
PR-M03-19-NI-057
Mar 21, 2019
Patent
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Sanofi
PR-M02-19-NI-059
Feb 26, 2019
Collaboration
Amgen, Cytokinetics and Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Amgen
PR-M02-19-NI-052
Feb 22, 2019
Collaboration
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
Abilita Bio, Inc.
PR-M02-19-NI-035
Feb 15, 2019
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Amgen
PR-M01-19-NI-079
Jan 28, 2019
Launch
GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification
GenScript
PR-M01-19-NI-050
Jan 17, 2019
Medical Device
Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
Amgen
PR-M01-19-NI-033
Jan 11, 2019
